Q-omics provides the consensus-scored TMEM239 profile across patient tissues and cancer cell-line models. TMEM239 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM239 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, TMEM239 RNA expression shows 6,684 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where TMEM239 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM239 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM239 survival associations across molecular data types. TMEM239 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM239 RNA expression–survival associations across cancer types. High TMEM239 expression shows unfavorable associations in KIRC, LUSC, CHOL, BRCA and UCS, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM239 RNA expression.
This table summarizes TMEM239 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM239. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM239 shows higher tumor expression in HNSC, BRCA, LUSC, LUAD and KIRC. The HNSC box plot shows higher TMEM239 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .002).
This table shows molecular features associated with TMEM239 in patient tissues and cancer cell lines. In patient samples, TMEM239 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM239 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
